141 posters, 8 videos, 8 audios, 5 topics, 442 authors, 228 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
6th World Congress on Vascular Access 2021
April 29 - 30, 2021 | Virtual

P055
Staff and patient evaluation of a new cyanoacrylate tissue adhesive with specific approval for use with vascular access devices
Poster Presenter
Authors
Affiliations
Part of Topic
Research & Innovations
Staff and patient evaluation of a new cyanoacrylate tissue adhesive with specific approval for use with vascular access devices
Background
The last 60 years has seen the development of cyanoacrylate adhesive from a purely industrial use to medical and now specifically vascular access use.
Until recently tissue adhesive licensing and guidance has been limited to its’ use on internal and external tissue primarily in skin closure (Corley et al, 2017).
Some tissue adhesive has now been given European CE mark approval for use with vascular access devices and one example of this is the SecurePortIV (Adhezion Biomedical LLC).
The Venous Access Team at St George’s Hospital in London had been using cyanoacrylate adhesive since first seeing the product at WoCoVA in 2016. There was however a little unease about using a product ‘off license’ and the product that was being used had a tendency to create a hard, crusty deposit around the vascular access device which could, in some cases become uncomfortable for the patient.
When the team became aware of the new SecurePortIV product, it was decided to trial its’ use at St George’s Hospital.
Objective
The objective was to introduce the SecurePortIV product and evaluate its’ performance through staff satisfaction and a case study
Case Study
The patient was a 65 year old woman with a diagnosis of metastatic HER2 positive breast cancer with bone and liver disease. There was a plan to commence a new treatment regime using Paclitaxel which is a highly vesicant intravenous medication (EMC 2020). Due to the risk of severe tissue damage if the drug should extravasate, it is recommended that this medication is delivered via a central venous access device. The patient was booked with the Venous Access Team for a peripherally inserted central catheter (PICC) insertion prior to starting treatment.
Method
Two questionnaires were devised – one for the patient and one for staff
Results
The patient scored each category with a 5 and her comment (related to bruising under the skin) was “I’ve always bled a lot”
The staff n=3 all scored each category with a 5 and comments included “Better than the previous glue…it doesn’t crystallize”, “Runny it takes time to dry” and “Takes a bit longer to dry and not very obvious when it is dry”
Conclusion
SecurePortIV tissue adhesive is a cyanoacrylate tissue adhesive that has been approved for use with vascular access devices and performs well in the vascular access setting. Staff need to be aware that the product needs time to dry once applied.
